Mental Health and Psychiatric Services in Nursing Homes

Mental health and psychiatric services in nursing homes address a population with high rates of diagnosable conditions — including major depression, anxiety disorders, schizophrenia, and behavioral symptoms of dementia — yet historically low rates of formal treatment. Federal regulations under the Nursing Home Reform Act and ongoing Centers for Medicare & Medicaid Services (CMS) oversight establish baseline requirements for mental health screening, assessment, and care planning. This page covers the regulatory framework, service delivery structures, clinical classifications, persistent tensions in care design, and reference comparisons across key mental health domains in long-term care settings.

Definition and Scope

Mental health and psychiatric services in nursing homes encompass the identification, assessment, diagnosis, and treatment of psychiatric disorders and behavioral disturbances in long-term care residents. The scope extends from routine mood screening embedded in the Minimum Data Set and Resident Assessment Instruments to formal psychiatric consultation, psychopharmacological management, and structured psychotherapy.

The resident population in skilled nursing facilities carries a disproportionate psychiatric burden. The National Nursing Home Survey and analyses published by the Agency for Healthcare Research and Quality (AHRQ) have documented that more than 65 percent of nursing home residents have at least one diagnosable psychiatric or behavioral condition (AHRQ, Mental Disorders and Nursing Home Admission, Publication No. 05-0025). Depression is the most prevalent discrete diagnosis, with estimates ranging from 20 to 40 percent of residents depending on screening instrument and facility type.

Federal scope is primarily defined through the Omnibus Budget Reconciliation Act of 1987 (OBRA '87), codified in 42 CFR Part 483 (the Nursing Home Reform Act provisions), which established a right to mental health services as part of the requirement that facilities provide care attaining or maintaining each resident's highest practicable physical, mental, and psychosocial well-being. CMS interprets this through the State Operations Manual (SOM), Appendix PP, which includes interpretive guidelines tied to F-tags such as F740 (Behavioral Health Services) and F758 (Unnecessary Medications, with specific provisions on psychotropic drugs).

Core Mechanics or Structure

Mental health service delivery in nursing homes operates through three overlapping structural layers: facility-based staff functions, contracted specialty services, and telehealth-augmented consultation.

Facility-based functions include nursing staff administering standardized mood and cognitive screening, social workers conducting psychosocial assessments, and activity staff implementing non-pharmacological behavioral interventions. The Social Work Services in Nursing Homes role carries particular responsibility for identifying psychosocial needs during admission and ongoing care planning cycles.

Contracted specialty services bring licensed clinical social workers (LCSWs), licensed professional counselors (LPCs), psychologists, and psychiatrists into the facility on a scheduled or as-needed basis. Under Medicare Part B, outpatient psychiatric services may be billed in a nursing facility setting for eligible beneficiaries, allowing practitioners to deliver individual or group psychotherapy with specific HCPCS billing codes (e.g., 90832–90838 for individual therapy; 90853 for group).

Telehealth-augmented consultation has expanded significantly following policy changes permitting remote psychiatric consultation in long-term care. CMS issued guidance confirming telehealth flexibilities applicable to nursing facilities under 42 CFR §410.78. The operational details of this delivery mode are addressed in Telehealth Services in Skilled Nursing Facilities.

The MDS 3.0 instrument is the clinical intake mechanism for mental health identification at the facility level. Section D of the MDS (Mood) uses the Patient Health Questionnaire-9 (PHQ-9) and the PHQ-9-OV (Observational Version), while Section E (Behavior) captures behavioral symptoms including physical and verbal behavioral symptoms directed toward others, and rejection of care. Triggered care area assessments (CAAs) for mood state and behavioral symptoms then feed directly into Care Planning and Interdisciplinary Team in Nursing Homes processes.

Causal Relationships or Drivers

Several structural and clinical factors drive elevated psychiatric morbidity in nursing home populations.

Admission selection effects: Nursing home admission itself is correlated with pre-existing psychiatric histories. A substantial share of admissions — estimated at 30 to 40 percent in analyses cited by CMS in the PASARR (Preadmission Screening and Resident Review) program documentation — involve individuals with serious mental illness (SMI), intellectual disability, or related conditions.

Preadmission Screening and Resident Review (PASARR): Under 42 CFR Part 483, Subpart C, all Medicaid-certified nursing facilities must screen applicants for SMI and intellectual disability before admission. Level I screening is conducted by the state Medicaid agency or its designee; Level II evaluation triggers specialized services determination. PASARR requirements represent the federal government's primary mechanism for routing individuals away from nursing homes when community-based alternatives exist, and for ensuring mental health services are available when nursing home placement is appropriate.

Neuropsychiatric symptoms of dementia: Behavioral and psychological symptoms of dementia (BPSD) — including agitation, aggression, wandering, and psychosis — are the most operationally intensive mental health challenge in most facilities. The Alzheimer's Association has published extensively on BPSD prevalence, estimating that up to 90 percent of individuals with dementia experience at least one neuropsychiatric symptom during the course of illness. The clinical and regulatory interface between BPSD and antipsychotic medication use connects directly to the Dementia and Memory Care Medical Services framework.

CMS National Partnership to Improve Dementia Care: Launched formally around 2012, this partnership set a measurable national target for reducing antipsychotic use in long-term care nursing homes. CMS published data showing reductions from baseline rates above 23 percent of long-stay residents receiving antipsychotics to rates below 14 percent by 2019 (CMS Quality, Safety & Education Portal data, cited in CMS Nursing Home Action Plan reports). This regulatory pressure has directly shaped how behavioral health services are structured and prioritized.

Classification Boundaries

Mental health services in nursing homes span three broad diagnostic-administrative categories:

1. Serious Mental Illness (SMI): Defined under federal PASARR regulations as schizophrenia, mood disorders (major depression, bipolar disorder), delusional disorders, and related conditions meeting clinical severity thresholds. Residents with SMI require specialized services plans appended to their standard care plans.

2. Organic and Neuropsychiatric Conditions: Includes dementia-associated behavioral symptoms, delirium, and behavioral manifestations of traumatic brain injury. These are clinically distinct from primary psychiatric disorders but share symptom overlap, complicating differential diagnosis.

3. Adjustment and Situational Conditions: Depression and anxiety arising as adjustment reactions to placement, functional decline, loss of autonomy, or grief. These may not reach diagnostic thresholds for major psychiatric classification but carry significant functional and quality-of-life impact and respond to structured psychosocial and psychological intervention.

Classification matters practically because it determines billing pathways, PASARR obligations, F-tag applicability, and which interdisciplinary team members carry primary responsibility. The Behavioral Health Interventions in Long-Term Care page addresses the intervention taxonomy that corresponds to these classifications.

Tradeoffs and Tensions

Pharmacological versus non-pharmacological approaches: CMS regulatory pressure under F758 and the National Partnership have created strong incentives to reduce antipsychotic prescribing. However, facilities serve residents with severe psychiatric conditions where antipsychotic therapy is clinically indicated and FDA-approved. The tension between population-level rate reduction targets and individual clinical necessity has prompted criticism from psychiatric professional societies, including the American Association for Geriatric Psychiatry (AAGP), who have published position statements cautioning against categorical prescribing restrictions that remove clinical discretion.

Staffing constraints and specialty access: Psychiatric consultation is typically available only through contracted visiting practitioners, creating gaps in continuity of care. Nursing Home Registered Nurse Staffing Requirements standards do not mandate psychiatric nursing specialization, meaning frontline identification of mental health deterioration depends on generalist nursing competency.

Resident autonomy versus protective intervention: Residents with SMI retain decision-making rights under 42 CFR §483.10. Compulsory psychiatric treatment in the nursing home setting is constrained by the same autonomy frameworks governing all nursing home care — see Resident Rights and Medical Decision-Making in Nursing Homes. This tension becomes acute when residents with SMI refuse psychotropic medications or behavioral health referrals.

Common Misconceptions

Misconception 1: Mental health conditions in nursing homes are inevitable and untreatable. Clinical evidence does not support this view. Structured interventions including cognitive-behavioral therapy adapted for older adults, problem-solving therapy, and group-based interventions have demonstrated efficacy in nursing home populations in research-based literature published in journals such as The Gerontologist and International Psychogeriatrics. CMS recognition of non-pharmacological approaches as preferred first-line strategies for BPSD codifies this evidence base in regulatory expectations.

Misconception 2: PASARR screening ensures all residents with SMI receive psychiatric services. PASARR Level II evaluations identify the need for specialized services, but the actual provision of those services depends on state implementation and available provider networks. The Government Accountability Office (GAO) has published findings — including GAO-08-51 — documenting inconsistency in PASARR implementation across states.

Misconception 3: Antipsychotic use reduction equates to improved psychiatric care quality. Reduction in antipsychotic prescribing is one metric within CMS quality reporting, but psychiatric care quality is multidimensional. A facility with low antipsychotic rates but inadequate psychotherapy access, insufficient psychiatric consultation, or undertreated depression does not necessarily deliver superior mental health care.

Misconception 4: Medicare Part A covers psychiatric services comprehensively during skilled nursing facility stays. Medicare Part A covers skilled nursing care under specific post-hospitalization qualifying criteria. Outpatient psychiatric therapy services in nursing facilities are typically billed under Medicare Part B, subject to 80 percent coverage after the Part B deductible — a cost-sharing structure that affects access for lower-income residents.

Checklist or Steps (Non-Advisory)

The following sequence reflects the standard regulatory and clinical process structure for mental health service identification and delivery in nursing homes, drawn from 42 CFR Part 483 requirements and CMS SOM Appendix PP:

  1. PASARR Level I screening — Completed for all applicants to Medicaid-certified facilities before admission. Identifies presence of SMI, intellectual disability, or related conditions.
  2. PASARR Level II evaluation — Triggered when Level I identifies potential SMI or intellectual disability; conducted by state-designated evaluator; produces specialized services determination.
  3. MDS 3.0 admission assessment — Section D (PHQ-9/PHQ-9-OV for mood), Section E (behavioral symptoms), Section C (cognitive function via BIMS or staff assessment) completed within required timeframes.
  4. Care Area Assessment (CAA) triggering — Positive screens on mood or behavior sections trigger formal CAAs; findings documented with decisions to proceed or not proceed to care planning.
  5. Care plan development — Interdisciplinary team develops individualized goals, interventions, and measurable outcomes for identified mental health conditions; resident and/or legal representative participation required.
  6. Psychiatric or psychological consultation — Ordered by the physician or Nurse Practitioner and Physician Assistant when diagnostic complexity, medication management, or psychotherapy access is indicated.
  7. Psychotropic medication review — Pharmacist and prescriber conduct gradual dose reduction (GDR) attempts for antipsychotics unless contraindicated; documentation of rationale required under F758.
  8. Non-pharmacological intervention implementation — Documented behavioral strategies (structured activity, sensory interventions, communication modifications) implemented and outcomes monitored.
  9. Quarterly and annual MDS reassessment — Mental health sections re-administered; care plan updated based on current resident status.
  10. Incident and adverse event documentation — Behavioral incidents, psychiatric emergencies, or medication adverse effects documented per facility policy and state reporting requirements.

Reference Table or Matrix

Domain Regulatory Authority Key Code/Document Primary Metric or Requirement
Behavioral Health Services CMS 42 CFR §483.40; F740 Individualized behavioral health care plan required
Psychotropic Medications CMS 42 CFR §483.45(e); F758 GDR required unless clinically contraindicated; documentation mandatory
PASARR Level I CMS / State Medicaid 42 CFR Part 483, Subpart C Required for all Medicaid-certified facility applicants
PASARR Level II CMS / State Medicaid 42 CFR §483.128–483.138 Triggered by SMI or ID identification; state-administered
MDS Mood Screening CMS MDS 3.0, Section D PHQ-9 administered; positive screen ≥ 10 triggers CAA
MDS Behavioral Symptoms CMS MDS 3.0, Section E Frequency and impact of behavioral symptoms coded
Antipsychotic Quality Measure CMS Nursing Home Compare / Five-Star Long-stay residents receiving antipsychotics; publicly reported
Medicare Part B Psychiatric Services CMS 42 CFR §410.49 Psychotherapy billable in nursing facility under Part B
Resident Rights (Psychiatric Care) CMS 42 CFR §483.10 Informed consent for treatment; right to refuse
Care Planning CMS 42 CFR §483.21 Interdisciplinary care plan within 21 days of admission

References

📜 3 regulatory citations referenced  ·  🔍 Monitored by ANA Regulatory Watch  ·  View update log

Explore This Site

Regulations & Safety Regulatory References Tools & Calculators Bmi Health Metrics Calculator